| Variable | Total | Screening detected | Symptoms | p-value |
| Age, mean(±SD) | 60.8 (±6.4) | 57.9 (±6.2) | 62.8 (±5.8) | <0.0001 |
| Age group [n (%)] |
|
|
| <0.0001 |
| 40 - 49 | 6 (5.0) | 6 (12.5) | 0 (0.0) | |
| 50 - 59 | 40 (33.6) | 22 (45.8) | 18 (25.4) | |
| 60 - 69 | 64 (53.8) | 18 (37.5) | 46 (64.8) | |
| ³70 | 9 (7.6) | 2 (4.2) | 7 (9.9) | |
| PSA, median (IQR) | 12.6 (8.6 - 19.7) | 11.2 (7.8 - 19.8) | 12.8 (9.4 - 20.3) | 0.446 |
| PSA group [n (%)] |
|
|
| 0.482 |
| £4.0 | 1 (0.8) | 0 (0.0) | 1 (1.4) | |
| 4.1 - 10.0 | 41 (34.4) | 20 (41.7) | 21 (29.6) | |
| 10.1 - 20.0 | 48 (40.3) | 16 (33.3) | 32 (45.1) | |
| >20.0 | 29 (24.4) | 12 (25.0) | 17 (23.9) | |
| Prostate volume, median (IQR) | 50.0 (40.0 - 60.0) | 50.0 (39.3 - 60.0) | 50.0 (40.0 - 63.6) | 0.741 |
| Risk Group [n (%)] |
|
|
| 0.547 |
| Low risk | 25 (21.0) | 11 (22.9) | 14 (19.7) | |
| Intermediate risk | 58 (48.7) | 25 (52.1) | 33 (46.5) | |
| High risk | 36 (30.3) | 12 (25.0) | 24 (33.8) |